Company MeiraGTx Holdings plc

Equities

MGTX

KYG596651029

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Ratings for MeiraGTx Holdings plc

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 01:30:00 27/04/2024 am IST			5-day change	1st Jan Change
4.8 ^USD	+1.91%		-5.70%	-31.62%

16/04	MeiraGTx Holdings plc Appoints Dr. Debra Yu to Serve on Each of the Compensation Committee and Science and Technology Committee of the Board	CI
14/03	MeiraGTx Holdings plc Reports Earnings Results for the Full Year Ended December 31, 2023	CI

MeiraGTx Holdings PLC is a vertically integrated, clinical-stage gene therapy company. The Company is focused on three distinct areas of unmet medical need: ocular diseases, including inherited retinal diseases (IRDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases. Its product pipeline includes botaretigene sparoparvovec or bota-vec, for the treatment of X-linked retinitis pigmentosa related to mutations in the retinitis pigmentosa GTPase regulator gene or XLRP-RPGR; AAV-hAQP1 for the treatment of radiation-induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogrenâs Syndrome; AAV-GAD for the treatment of Parkinsonâs Disease; AAV-RPE65 for the treatment of RPE65-asociated retinal dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of achromatopsia; AAV-AIPL1 for the treatment of LCA4, and AAV-RDH12 for the treatment of RDH12 mutation-associated retinal dystrophy.

Number of employees: 422

USD in Million	2022	Weight	2023	Weight	Delta
Retinal Drugs and Gene Therapies 100.0 %	16	100.0 %	14	100.0 %	-11.95%

USD in Million	2022	Weight	2023	Weight	Delta
United Kingdom 100.0 %	16	100.0 %	14	100.0 %	-11.95%

Managers	Title	Age	Since
Richard Giroux FOU	Founder	61	20/15/20
Alexandria Forbes CEO	Chief Executive Officer	59	20/15/20
Robert Zeldin CTO	Chief Tech/Sci/R&D Officer	61	05/20/05
Elizabeth Anderson IRC	Investor Relations Contact	-	01/19/01
Tim Randall AUD	Comptroller/Controller/Auditor	-	01/19/01
Robert Wollin LAW	General Counsel	48	01/19/01
Stuart Naylor PRN	Corporate Officer/Principal	61	01/15/01

Members of the board	Title	Age	Since
Debra Yu BRD	Director/Board Member	59	25/22/25
Thomas Shenk BRD	Director/Board Member	77	01/15/01
Keith Harris CHM	Chairman	71	01/15/01
Nicole Seligman BRD	Director/Board Member	66	10/19/10
Alexandria Forbes CEO	Chief Executive Officer	59	20/15/20
Stuart Naylor PRN	Corporate Officer/Principal	61	01/15/01
Martin Indyk BRD	Director/Board Member	72	21/19/21
Ellen Hukkelhoven BRD	Director/Board Member	37	01/17/01
Neil Mendoza BRD	Director/Board Member	64	01/15/01

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	64,306,613	41,837,254 ( 65.06 %)	0	65.06 %

Name	Equities	%	Valuation
Perceptive Advisors LLC 17.82 %	11,331,103	17.82 %	69 M $
Johnson & Johnson Innovation - JJDC, Inc. 10.44 %	6,641,064	10.44 %	40 M $
Adage Capital Partners GP LLC 8.321 %	5,291,618	8.321 %	32 M $
SANOFI 7.387 %	4,697,737	7.387 %	29 M $
Prosight Management LP 6.369 %	4,050,714	6.369 %	25 M $
683 Capital Management LLC 3.931 %	2,500,000	3.931 %	15 M $
BlackRock Advisors LLC 3.301 %	2,099,031	3.301 %	13 M $
Alexandria Forbes 2.204 %	1,401,489	2.204 %	9 M $
Richard Giroux 1.463 %	930,578	1.463 %	6 M $
Royce & Associates LP 1.057 %	672,115	1.057 %	4 M $

MeiraGTx Holdings Plc

450 East 29th Street 14th floor

10016, New York

+646 860 7985

http://www.meiragtx.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.8 USD

Average target price

21.6 USD

Spread / Average Target

+350.00%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
MEIRAGTX HOLDINGS PLC	-31.62%	309M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs